Cargando…

Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle

PURPOSE: Docetaxel, a chemotherapeutic agent, induces high rates of transient chemotherapy-induced amenorrhea (CIA) when used as adjuvant chemotherapy for premenopausal women with breast cancer. Clinical laboratory data to assess the hormonal environment implicated in inducing transient CIA was asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshimura, Keiko, Furuya, Yoshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112198/ https://www.ncbi.nlm.nih.gov/pubmed/25077063 http://dx.doi.org/10.1186/2193-1801-3-352

Ejemplares similares

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.
por: Bianco, A. R., et al.
Publicado: (1991)

Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients
por: Jeon, Se Jeong, et al.
Publicado: (2016)

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
por: Berliere, Martine, et al.
Publicado: (2008)

Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer
por: Kabirian, Rayan, et al.
Publicado: (2023)

Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer: a meta-analysis of the literature
por: Zhou, Qiong, et al.
Publicado: (2015)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal Women With Breast Cancer: An Updated Meta-Analysis
por: Wang, Yifei, et al.
Publicado: (2022)

Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
por: Zhou, Wen-Bin, et al.
Publicado: (2010)

Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: Putative mechanisms within the neutrophil pool system
por: Furuya, Yoshihiko
Publicado: (2019)

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
por: Jensen, Maj-Britt, et al.
Publicado: (2018)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide
por: D’Avila, Ângela Marcon, et al.
Publicado: (2015)

Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2020)

Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
por: Batra, Atul, et al.
Publicado: (2020)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.
por: Bruning, P. F., et al.
Publicado: (1990)

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy
por: Li, Hai, et al.
Publicado: (2019)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2021)

Amenorrhea and Menopause in Patients with Breast Cancer after Chemotherapy
por: Shin, Jae Jun, et al.
Publicado: (2019)

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
por: Vasey, P A, et al.
Publicado: (2002)

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea
por: Zhou, Juan, et al.
Publicado: (2015)

SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study
por: Reimer, Toralf, et al.
Publicado: (2016)

Primary amenorrhea after bone marrow transplantation and adjuvant chemotherapy misdiagnosed as disorder of sex development: A case report
por: Huang, He, et al.
Publicado: (2016)

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
por: Adeel, Muhammad, et al.
Publicado: (2019)

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2020)

High Serum Estradiol Reduces Acute Hepatotoxicity Risk Induced by Epirubicin Plus Cyclophosphamide Chemotherapy in Premenopausal Women with Breast Cancer
por: Huang, Shunmin, et al.
Publicado: (2021)

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
por: Chen, Lu, et al.
Publicado: (2018)

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin
por: Yeo, Winnie, et al.
Publicado: (2022)

The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
por: Zhou, Wenbin, et al.
Publicado: (2012)

Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)

Chemotherapy-induced amenorrhea in patients suffering from breast cancer in the Northwest of Iran
por: Eivazi-Ziaei, Jamal, et al.
Publicado: (2014)

Evaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea
por: Zhang, Bailin, et al.
Publicado: (2018)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2015)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Advanced Stage Is a Risk for Severe Neutropenia in Breast Cancer Patients Undergoing Neoadjuvant Adriamycin/Cyclophosphamide/Docetaxel Chemotherapy
por: Moro, Kazuki, et al.
Publicado: (2022)

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

Higher prevalence of clinical cardiovascular comorbidities in postmenopausal women with self-reported premenopausal hirsutism and/or oligo-amenorrhea
por: Comim, F. V., et al.
Publicado: (2017)

Grover disease associated with docetaxel chemotherapy
por: Afvari, Shawn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_343ua70hjjpns0ufkhdg5uu55q